tiprankstipranks
Tonix Pharma Secures Defense Contract for Antiviral Development
Company Announcements

Tonix Pharma Secures Defense Contract for Antiviral Development

Don't Miss our Black Friday Offers:

An update from Tonix Pharma ( (TNXP) ) is now available.

Tonix Pharmaceuticals Holding Corp. has received its first payment from the Defense Threat Reduction Agency to develop antiviral agents aimed at enhancing military personnel’s readiness against biological threats. This strategic focus on broad-spectrum antivirals highlights the company’s potential growth opportunities and underscores the importance of innovation in the defense sector. Investors should note the inherent risks and uncertainties associated with forward-looking statements regarding the company’s future performance.

For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTonix Pharmaceuticals presents data, analyses of TNX-102 SL effects
TipRanks Auto-Generated NewsdeskTonix Pharma Reveals Promising TNX-801 Vaccine Data
TheFlyTonix Pharmaceuticals announces publication of study on tolerability of TNX-801
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App